XBiotech (NASDAQ:XBIT) Stock Price Crosses Above 50 Day Moving Average of $7.45

Shares of XBiotech Inc. (NASDAQ:XBITGet Free Report) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $7.45 and traded as high as $8.39. XBiotech shares last traded at $8.21, with a volume of 45,963 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of XBiotech in a research note on Thursday, February 15th. They set a “sell” rating for the company.

Read Our Latest Research Report on XBiotech

XBiotech Stock Performance

The firm has a market cap of $249.99 million, a P/E ratio of -10.01 and a beta of 1.45. The stock’s 50 day simple moving average is $7.45 and its 200 day simple moving average is $5.39.

XBiotech (NASDAQ:XBITGet Free Report) last announced its quarterly earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter.

Hedge Funds Weigh In On XBiotech

An institutional investor recently bought a new position in XBiotech stock. National Bank of Canada FI acquired a new position in shares of XBiotech Inc. (NASDAQ:XBITFree Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 24,347 shares of the biopharmaceutical company’s stock, valued at approximately $103,000. National Bank of Canada FI owned about 0.08% of XBiotech at the end of the most recent reporting period. 55.70% of the stock is owned by institutional investors and hedge funds.

XBiotech Company Profile

(Get Free Report)

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.

Featured Stories

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.